Yang et al. (2016) found that downregulation of miRNA-375 could inhibit the proliferation, migration and chemo-sensitivity of pancreatic cancer by combining with HOXB3. Chen et al. (2013) and others showed that HOXB3 could promote the progression of prostate cancer cells by activating CDCA3. Miller et al. (2018) and others demonstrated that HOXA4/HOXB3 gene expression could be used as a marker of recurrence, after primary cytoreductive surgery and first-line adjuvant chemotherapy, for high-grade serious ovarian cancer. This evidence concerns the gene HOXB3 and prostate carcinoma.